Tumor-immune signatures of treatment resistance to brentuximab vedotin with ipilimumab and/or nivolumab in Hodgkin lymphoma.

Edgar G Kozlova Hsin-Hui Huang Opeyemi A Jagede Kevin Tuballes Diane M Del Valle Geoffrey Kelly Manishkumar Patel Hui Xie Jocelyn Harris Kimberly Argueta Kai Nie Vanessa Barcessat Radim Moravec Jennifer Altreuter Dzifa Yawa Duose Brad S Kahl Stephen M Ansell Joyce Yu Ethan Cerami James R Lindsay Ignacio I Wistuba Seunghee Kim-Schulze Catherine S Diefenbach Sacha Gnjatic

Published in: Cancer research communications (2024)

The results suggest a circulating tumor-immune-derived signature of BV±I+N treatment resistance that may be useful for patient stratification in combination checkpoint therapy.

Keyphrases

hodgkin lymphoma
dna damage
case report
cell proliferation
mesenchymal stem cells
lipopolysaccharide induced
combination therapy
lps induced
inflammatory response
replacement therapy